Biogen and Ionis to Advance Diranersen into Phase 3 Clinical Trial After Phase 2 Study Confirms Cognitive Decline Inhibition
Phase 2 Clinical Trial of Diranersen Demonstrates Cognitive Decline Delay Efficacy
Biogen (BIIB) and Ionis (IONS), co-developers of the antisense oligonucleotide (ASO) therapeutic diranersen, have announced positive data from the Phase 2 Celia study. Diranersen works by inhibiting MAPT mRNA, which regulates the synthesis of tau protein, thereby preventing the formation of protein tangles. The clinical results showed that the 60mg low-dose group exhibited up to a 50% improvement in cognitive function assessment indicators compared to the placebo group. Although the primary endpoint was not fully met due to insufficient dose-response evidence, the observed decline delay effect in the low-dose group supports the decision to move the drug into Phase 3 clinical trials.
Scientific Rationale for Targeting Tau Beyond Amyloid
The Alzheimer's Disease (AD) therapeutic market has primarily focused on removing amyloid-beta, but this approach has faced limitations in efficacy and has been associated with adverse effects such as cerebral edema. Tau protein accumulates inside nerve cells and is closely associated with cognitive decline, making it a promising complement to amyloid-beta therapies. Notably, diranersen exhibits a higher safety profile with a lower risk of amyloid-related imaging abnormalities (ARIA), a common side effect of existing therapies. By inhibiting the accumulation of intrinsically toxic proteins, it has the potential to halt disease progression, demonstrating its value as a next-generation therapeutic.
Licensing Agreement Terms and Competitive Landscape for Global Development
In December 2019, Biogen acquired exclusive rights to diranersen from Ionis for a total of $200 million, including an upfront payment of $45 million and milestone payments of $155 million. Biogen agreed to pay royalties in the low-to-mid teens upon successful commercialization, significantly strengthening its Alzheimer's portfolio. Voyager (VYGR) is currently developing VY1706, a pre-clinical stage siRNA pipeline, and other companies are also developing tau-targeting drugs. Among these, Biogen is leading the way by advancing diranersen into Phase 3 clinical trials.
The Dawn of Alzheimer's Combination Therapy and Market Outlook
Clinical experts anticipate that diranersen will evolve beyond a standalone therapy and become part of a combination therapy with existing amyloid antibodies. Combining antibodies that remove plaques outside the brain with oligonucleotides that prevent the breakdown of the tau protein inside the brain could maximize therapeutic synergy. Biogen plans to finalize the optimal dose during the Phase 3 clinical trials, which will be crucial for capturing a significant share of the rapidly growing global Alzheimer's market. The success of diranersen in clinical trials will be a key indicator of the success of the paradigm shift towards multi-target Alzheimer's therapies.
Diranersen demonstrated efficacy in the Phase 2 Celia study, delaying cognitive decline (ADAS-Cog, MMSE) by up to 42-50% in the 60mg low-dose group compared to placebo, confirming its advancement into Phase 3 clinical trials. This signifies a turning point in the global Alzheimer's therapeutic market, as it shifts from a focus on amyloid-beta to tau protein modulation, and diranersen is currently the most advanced pipeline in this area. In the medium to long term, diranersen, with its low risk of adverse effects, is expected to establish itself as a standard for both standalone therapy and multi-target combination therapy with existing approved treatments such as Leqembi and Kisqali, driving the growth of the global Alzheimer's treatment market, which is projected to reach approximately $38 billion by 2035. Furthermore, its faster clinical development and superior safety profile compared to competitors such as Voyager (VY1706) and Denali are expected to further strengthen Biogen's neurology portfolio.